MediciNova
Update in progressMNOV (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
MediciNova, Inc. is a biopharmaceutical company developing novel small-molecule therapies for serious, underserved diseases in the United States. Its lead MN-166 (ibudilast) is an oral anti-inflammatory and neuroprotective agent in Phase 2 trials for neurological diseases such as MS and ALS, plus neuropathy and ARDS prevention. MN-001 (tipelukast) targets fibrotic and metabolic disorders, including NAFLD and hypertriglyceridemia. Founded 2000, La Jolla, California.
Company score
- Sentiment
- 0.09
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.00
- Governance
- 0.00
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.00
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.04
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!